Lexaria Bioscience Corp. (LEXX): Nasdaq/NYSE listing notice — Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure

Lexaria Bioscience Corp.

Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).
Compliance period runs 180 calendar days, until August 3, 2026, to regain compliance.
To cure, closing bid price must be ≥$1.00 for at least 10 consecutive business days during period.
If not cured, company may seek second 180-day period if it meets other initial listing standards.
Failure to regain compliance could lead to delisting; company is evaluating options.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lexaria Bioscience Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Lexaria Bioscience Corp. filing history →

Source: SEC EDGAR

accession 0001640334-26-000230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.